Search Results - "ROBINET, G"

Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01) by Barlesi, F., Gervais, R., Lena, H., Hureaux, J., Berard, H., Paillotin, D., Bota, S., Monnet, I., Chajara, A., Robinet, G.

“…Brain metastases (BM) occur in up to 40% of non-small-cell lung cancer (NSCLC) patients. This trial assessed the safety and efficacy of pemetrexed–cisplatin in…”
Get full text

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial by Remon, J., Besse, B., Aix, S. Ponce, Callejo, A., Al-Rabi, K., Bernabe, R., Greillier, L., Majem, M., Reguart, N., Monnet, I., Cousin, S., Garrido, P., Robinet, G., Garcia Campelo, R., Madroszyk, A., Mazières, J., Curcio, H., Wasąg, B., Pretzenbacher, Y., Fournier, B., Dingemans, A.-M.C., Dziadziuszko, R.

“…The APPLE trial aimed to evaluate the feasibility of longitudinal plasma epidermal growth factor receptor (EGFR) T790M monitoring for the best sequencing…”
Get full text

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1 by Besse, B., Felip, E., Garcia Campelo, R., Cobo, M., Mascaux, C., Madroszyk, A., Cappuzzo, F., Hilgers, W., Romano, G., Denis, F., Viteri, S., Debieuvre, D., Galetta, D., Baldini, E., Razaq, M., Robinet, G., Maio, M., Delmonte, A., Roch, B., Masson, P., Schuette, W., Zer, A., Remon, J., Costantini, D., Vasseur, B., Dziadziuszko, R., Giaccone, G., Zemanová, M., Besse, B., Bonnet, C., Cadranel, J., Chouaid, C., Cortot, A., Debieuvre, D., Delclaux, B., Denis, F., Duchemann, B., El Kouri, C., Ferrand, F.R., Ginoux, M., Hilgers, W., Madroszyk, A., Masson, P., Mazieres, J., Molinier, O., Moro-Sibilot, D., Pichon, E., Mascaux, C., Robinet, G., Roch, B., Zalcman, G., Schmidtke-Schrezenmeier, G., Schuette, W., Urban, L., Gottfried, M., Nechushtan, H., Peled, N., Wollner, M., Zer, A., Baldini, E., Bonanno, L., Bonetti, A., Cappuzzo, F., Delmonte, A., Galetta, D., Maio, M., Minotti, V., Rea, A., Romano, G., Tassinari, D., Tonini, G., Dziadziuszko, R., Karaszewska, B., Szczęsna, A., Cobo, M., De Castro, J., Felip, E., Garcia Campelo, M.R., Hernández, A., Moran, T., Provencio, M., Viteri, S., Dasgupta, A., Gabrail, N., Giaccone, G., Harshad, A., Liu, S., Oubre, D., Panikkar, R., Razaq, M., Sanborn, R.

“…Patients with advanced non-small-cell lung cancer (NSCLC) treated with immune checkpoint blockers (ICBs) ultimately progress either rapidly (primary…”
Get full text

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer by Rosell, R., Robinet, G., Szczesna, A., Ramlau, R., Constenla, M., Mennecier, B. C., Pfeifer, W., O'Byrne, K. J., Welte, T., Kolb, R., Pirker, R., Chemaissani, A., Perol, M., Ranson, M. R., Ellis, P. A., Pilz, K., Reck, M.

“…Background: The Lung Cancer Cetuximab Study is an open-label, randomized phase II pilot study of cisplatin and vinorelbine combined with the epidermal growth…”
Get full text

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC by Cho, B.C., Reinmuth, N., Lee, K.H., Ahn, M.-J., Luft, A., Van den Heuvel, M., Dols, M. Cobo, Smolin, A., Vicente, D., Moiseyenko, V., Antonia, S.J., Moulec, S. Le, Robinet, G., Natale, R., Garon, E.B., Nakagawa, K., Liu, F., Thiyagarajah, P., Peters, S., Rizvi, N.A.

Get full text

Nivolumab in non-small cell lung cancer: French evaluation of use, current practices and medico-economic approach by Grude, F., Corre, R., Urban, T., Bennouna, J., De Chabot, G., Chatellier, T., Denis, F., Descourt, R., Douillard, J.-Y., Ricordel, C., Molinier, O., Pinquie, F., Robinet, G., Travers, M., Moiteaux, B., Deniel Lagadec, D., Marhuenda, F.

Get full text

Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort by Domblides, C., Monnet, I., Mazieres, J., Barlesi, F., Gounant, V., Baldacci, S., Mennecier, B., Toffart, A.C., Audigier Valette, C., Doucet, L., Giroux-Leprieur, E., Guisier, F., Molinier, O., Perol, M., Pichon, E., Robinet, G., Templement Grangerat, D., Ruppert, A.-M., Wislez, M.

Get full text

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study) by Raynaud, C, Greillier, L, Mazieres, J, Monnet, I, Mastroianni, B, Robinet, G, Fraboulet, G, Dixmier, A, Berard, H, Lamy, R, Letreut, J, Lena, H, Oliviero, G, Botta, S, Vergnenegre, A, Borget, I, Chouaid, C

“…Malignant pleural mesothelioma (MPM) is a rare disease with poor prognosis in spite of significant improvement in survival, due to new chemotherapy regimens…”
Get full text

Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors by Marty, M., Fumoleau, P., Adenis, A., Rousseau, Y., Merrouche, Y., Robinet, G., Senac, J., Puozzo, C.

“…Summary Background Vinorelbine is a vinca alkaloid obtained by hemi-synthesis, which makes the molecule more lipophilic than the other vincas An injectable…”
Get full text

Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer : Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1 by ROBINET, G, THOMAS, P, FOURNEL, P, QUOIX, E, RIOU, R, REBATTU, P, PEROL, M, PAILLOTIN, D, MORNEX, F, BRETON, J. L, LENA, H, GOUVA, S, DABOUIS, G, BENNOUNA, J, SOUQUET, P. J, BALMES, P, THIBERVILLE, L

“…To determine if the timing of whole brain radiotherapy (WBRT) with respect to chemotherapy with cisplatin and vinorelbine would influence survival in patients…”
Get full text

127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population by Garon, E.G, Rizvi, N.A, Leighl, N.B, Hui, R, Eder, J.P, Patnaik, A, Aggarwal, C, Horn, L, Balmanoukian, A.S, Gubens, M.A, Felip-Font, E, Costa, E. Carceny, Soria, J.C, Ahn, M.J, Arkenau, H.T, Lee, J.S, Robinet, G, Lubiniecki, G.M, Zhang, J, Emancipator, K, Rutledge, R, Dolled-Filhart, M, Gandhi, L

Get full text

Systemic treatment of brain metastases from lung cancer by Barlesi, F, Spano, J-P, Cortot, A B, Carpentier, A F, Robinet, G, Besse, B

“…Systemic treatment of lung cancer patients with brain metastases is based on clinical (presence of symptomatic intracranial lesions), pathological and…”
Get full text

Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study by Cortot, AB, Gerinière, L, Robinet, G, Breton, J-L, Corre, R, Falchero, L, Berard, H, Gimenez, C, Chavaillon, J-M, Perol, M, Bombaron, P, Mercier, C, Souquet, P-J

“…Background: Brain metastases (BM) considerably worsen the prognosis of non-small-cell lung cancer (NSCLC) patients. The usefulness and choice of chemotherapy…”
Get full text

Randomized multicentric phase II study of carboplatin /gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie) by THOMAS, P, ROBINET, G, KLEISBAUER, J. P, GOUVA, S, FOURNEL, P, LENA, H, LE CAER, H, PEROL, M, BERARD, H, BOMBARON, P, VERGNENEGRE, A

“…To evaluate the efficacy and safety of gemcitabine and carboplatin in the treatment of previously untreated patients with advanced non-small cell lung cancer…”
Get full text

Evaluation of preoperative non-invasive ventilation in thoracic surgery for lung cancer: the preOVNI study GFPC 12-01 by Paleiron, N, André, M, Grassin, F, Chouaïd, C, Venissac, N, Margery, J, Couturaud, F, Noël-Savina, E, Tromeur, C, Vinsonneau, U, Vedrine, L, Leroyer, C, Nowak, E, Berard, H, Thomas, P, Brouchet, L, Bagan, P, Fournel, P, Mottier, D, Robinet, G

“…Surgical resection is the best treatment for stage I and II non-small cell lung cancer. Despite an improvement in the perioperative management of cancer…”
Get more information

P67 Antitumour activity of pemetrexed (Pem) and carboplatin in elderly patients in IIIb and IV stages of non small cell lung cancer (NSCLC): a multicenter phase II study by Gervais, R, Robinet, G, Clement-Duchene, C, Denis, F, El Koury, C, Martin, P, Thareau-Vaury, A, Chouaki, N, Bourayou, N, Morère, J.F

Get full text

Phase II Trial of Paclitaxel and Carboplatin in Metastatic Small-Cell Lung Cancer: A Groupe Français de Pneumo-Cancérologie Study by THOMAS, Y. P, CASTELNAU, O, PERDU, D, POIRIER, R, POMMIER DE SANTI, P, PENOT-RAGON, C, KLEISBAUER, J. P, PAILLOTIN, D, LENA, H, ROBINET, G, MUIR, J. F, DELAVAL, P, GOUVA, S, BALMES, P, BLANCHON, F

“…To evaluate the efficacy and safety of paclitaxel and carboplatin in the treatment of previously untreated patients with metastatic small-cell lung cancer…”
Get full text

FDG PET in Epithelioid Hemangioendothelioma by Rest, C Cheze-Le, Botton, E, Robinet, G, Conan-Charlet, V, Bizais, Y, Visvikis, D

“…Epithelioid hemangioendothelioma (EH) is an uncommon tumor of endothelial origin. It can develop in any tissue and can be multicentric or metastatic. The usual…”
Get full text

Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer : A phase II trial conducted by the Groupe Français de Pneumo-Cancérologie (GFPC) by VERGNENEGRE, A, DANIEL, C, PREUX, P. M, ROBINET, G, LENA, H, FOURNEL, P, KLEISBAUER, J. P, LE CAER, H, LETREUT, J, PAILLOTIN, D, PEROL, M, BOUCHAERT, E

“…The most satisfactory treatment for patients with locally advanced non-small-cell lung cancer (NSCLC) is combination chemotherapy-radiotherapy (CT-RT). The…”
Get full text

Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer by Thomas, P., Robinet, G., Gouva, S., Fournel, P., Léna, H., Le Caer, H., Perol, M., Berard, H., Bombaron, P., Vergnenegre, A., Kleisbauer, J.P.

“…To evaluate the efficacy and safety of gemcitabine and carboplatin in the treatment of previously untreated patients with advanced non-small cell lung cancer…”
Get full text